Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group

Chirality. 2012 Apr;24(4):289-93. doi: 10.1002/chir.21995. Epub 2012 Feb 17.

Abstract

This work reports the result of the enantioselective disposition of pantoprazole, omeprazole, and lansoprazole in a same group of Brazilian health subjects. Ten nongenotyped healthy subjects were used for this study. Each subject received a single oral dose of 80 mg of pantoprazole, 40 mg of omeprazole, and 30 mg of lansoprazole, and the plasma concentrations of the enantiomers were measured for 8 h postdose. For pantoprazole and omeprazole, among the 10 volunteers investigated, only one volunteer (Subject # 4) presented higher plasma concentrations of the (+)-enantiomer than those of (-)-enantiomer. Nevertheless, the area under the concentration-time curve of the (+)-lansoprazole was higher than those the (-)-lansoprazole for all subjects. The comparison of proton pump inhibitors' enantiomers disposition from a single group volunteer demonstrated that pantoprazole and omeprazole can be used to differentiate extensive from poor CYP2C19 metabolizer while lansoprazole cannot do it.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / blood
  • 2-Pyridinylmethylsulfinylbenzimidazoles / chemistry
  • 2-Pyridinylmethylsulfinylbenzimidazoles / pharmacokinetics
  • Adolescent
  • Adult
  • Brazil
  • Humans
  • Lansoprazole
  • Middle Aged
  • Omeprazole / blood
  • Omeprazole / chemistry
  • Omeprazole / pharmacokinetics
  • Pantoprazole
  • Proton Pump Inhibitors / blood
  • Proton Pump Inhibitors / chemistry*
  • Proton Pump Inhibitors / pharmacokinetics*
  • Stereoisomerism
  • Substrate Specificity
  • Young Adult

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Proton Pump Inhibitors
  • Lansoprazole
  • Pantoprazole
  • Omeprazole